Individual is unable to complete three prior lines of therapy due to
contraindication(s) (e.g. fluoropyrimidine-based chemotherapy [e.g.,
fluorouracil or capecitabine]; oxaliplatin-based chemotherapy; irinotecan-based
chemotherapy; anti-VEGF therapy [e.g., bevacizumab]; anti-EGFR therapy
[e.g., panitumumab or cetuximab] if KRAS wild type mCRC)